MLANA and neoplasm: Interestingly, when animals were vaccinated with non-specific Gag-VLP, the therapeutic advantage of lymphatic dosing of αCTLA-4 was lost, as tumor sizes were similar to the control group and greater than the treatment groups (isotype IgG2b, i.d.; isotype IgG2b, i.d. + Melan-A VLP; αCTLA-4, i.d. + Melan-A VLP; and αCTLA-4 i.d.; Figure 4C and Supplemental Figure S2).